Jeffrey A Kahn, MD

Professor of Clinical Medicine

Image of Jeffrey A Kahn, MD
Is this your profile? Click to edit

Overview

Dr. Kahn is the medical director of the USC Liver Transplant Program. He received fellowship training in gastroenterology and transplant hepatology from the Keck School of Medicine and Cedars-Sinai Medical Center. He is board certified in internal medicine, gastroenterology and transplant hepatology.

Dr. Kahn’s primary research interests are in liver transplantation, hepatocellular carcinoma and viral hepatitis. He has written and co-authored several abstracts and peer-reviewed articles on various topics such as chronic hepatitis C and liver transplantation. He is also a distinguished lecturer.

Awards

  • Alpha Omega Alpha, 1990

Publications

  • A retrospective analysis of rates of dermatology follow-up and new skin cancer diagnosis among solid organ transplant recipients during the COVID-19 pandemic JAAD Int. 2023 Mar; 10:53-54. . View in PubMed
  • Impact of Bacteria Types on the Clinical Outcomes of Spontaneous Bacterial Peritonitis Dig Dis Sci. 2023 05; 68(5):2140-2148. . View in PubMed
  • Living donor liver paired exchange between pediatric and adult recipients due to donor graft size mismatch Am J Transplant. 2023 03; 23(3):440-442. . View in PubMed
  • Clinical Significance of Ascitic Fluid Polymorphonuclear Leukocyte Percentage in Patients With Cirrhosis Without Spontaneous Bacterial Peritonitis Clin Transl Gastroenterol. 2023 09 01; 14(9):e00614. . View in PubMed
  • Addressing sex-based disparities in liver transplantation Curr Opin Organ Transplant. 2023 04 01; 28(2):110-116. . View in PubMed
  • Vaccination for coronavirus disease 2019 in liver transplantation candidates should be recommended but not mandated Clin Liver Dis (Hoboken). 2022 Nov; 20(5):154-156. . View in PubMed
  • A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation Transpl Infect Dis. 2022 Feb; 24(1):e13751. . View in PubMed
  • Excess liver transplant waitlist mortality for patients with primary biliary cholangitis under MELD-Na allocation Clin Transplant. 2022 02; 36(2):e14527. . View in PubMed
  • Treatment and outcomes of hepatocellular carcinoma in patients with Sickle cell disease: a population-based study in the US. HPB (Oxford). 2022 02; 24(2):234-243. . View in PubMed
  • A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients Transplantation. 2022 02 01; 106(2):e153-e157. . View in PubMed
  • Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis Transpl Int. 2022; 35:10182. . View in PubMed
  • Reply to: Comments on: Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis Transpl Int. 2022; 35:10679. . View in PubMed
  • Transfusion-free Retransplantation for Post-liver Transplantation Hepatic Artery Thrombosis: How Much Augmentation Is Too Much? Transplant Direct. 2021 Nov; 7(11):e776.. View in PubMed
  • Autoimmune hepatitis triggered by COVID-19 Intern Med J. 2021 Jul; 51(7):1182-1183. . View in PubMed
  • Use of Hepatitis B Virus-Positive Organs in Organ Transplantation Clin Liver Dis. 2021 11; 25(4):841-857. . View in PubMed
  • We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases Hepatology. 2021 11; 74(5):2876-2887. . View in PubMed
  • A Healthy Liver After SVR: Food for Thought Dig Dis Sci. 2021 06; 66(6):1778-1779. . View in PubMed
  • IgG:IgM Ratios of Liver Plasma Cells Reveal Similar Phenotypes of Primary Biliary Cholangitis With and Without Features of Autoimmune Hepatitis Clin Gastroenterol Hepatol. 2021 02; 19(2):397-399. . View in PubMed
  • Applying the original model for end-stage liver disease score rather than the model for end-stage liver disease-Na score for risk stratification prior to transjugular intrahepatic portosystemic shunt procedures Eur J Gastroenterol Hepatol. 2021 04 01; 33(4):541-546. . View in PubMed
  • Impact of Morbid Obesity on Liver Transplant Candidacy and Outcomes: National and Regional Trends Transplantation. 2021 05 01; 105(5):1052-1060. . View in PubMed
  • Treatment and Outcomes of Early Stage Breast Cancer in Patients with Hepatic Dysfunction J Surg Res. 2020 12; 256:212-219. . View in PubMed
  • The use of organs from hepatitis C virus-viremic donors into uninfected recipients Curr Opin Organ Transplant. 2020 12; 25(6):620-625. . View in PubMed
  • Liver transplantation as therapy for hepatocellular carcinoma Liver Int. 2020 02; 40 Suppl 1:116-121. . View in PubMed
  • Diagnosis of Focal Nodular Hyperplasia (FNH) after Liver Transplantation Case Rep Transplant. 2020; 2020:8824099. . View in PubMed
  • Comparison of Skin Cancer Incidence in Caucasian and Non-Caucasian Liver VsLung Transplant Recipients: A Tale of Two Regimens. Clin Drug Investig. 2019 Feb; 39(2):197-203. . View in PubMed
  • Assessment of Fibrosis in Liver Transplant Recipients: Diagnostic Performance of Shear Wave Elastography (SWE) and Correlation of SWE Findings With Biopsy Results AJR Am J Roentgenol. 2019 12; 213(6):W264-W271. . View in PubMed
  • Intentional Transmission of Hepatitis C With Organ Transplantation: With Opportunity Comes Responsibility Transplantation. 2019 11; 103(11):2215-2216. . View in PubMed
  • Hepatorenal Syndrome Clin J Am Soc Nephrol. 2019 05 07; 14(5):774-781. . View in PubMed
  • Reply Gastroenterology. 2017 07; 153(1):328-329. . View in PubMed
  • Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver TransplantationGastroenterology. 2017 02; 152(3):550-553. e8. . View in PubMed
  • Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation Transplant Direct. 2015 Jul; 1(6):e21. . View in PubMed
  • Imaging appearance in acute liver failure: correlation with clinical and pathology findings Dig Dis Sci. 2014 Aug; 59(8):1987-95. . View in PubMed
  • Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis CGastroenterology. 2010 Jun; 138(7):2321-312331. e1-2. . View in PubMed
  • Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial Hepatology. 2006 Dec; 44(6):1675-84. . View in PubMed
  • Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial Am J Gastroenterol. 2006 May; 101(5):983-92. . View in PubMed
  • Live donor liver transplantation without blood products: strategies developed for Jehovah’s Witnesses offer broad application Ann Surg. 2004 Aug; 240(2):350-7. . View in PubMed